In multiple myeloma (MM), allogeneic bone marrow transplantation may produce complete and durable responses, but is accompanied by significant transplantrelated mortality (TRM). To assess feasibility and possible advantages offered by the use of allogeneic, growth factor-primed PBSC instead of marrow, we analyzed the data of 10 patients with MM (IgG = 6, IgA = 1, BJ = 2, non-secreting = 1; stage II = 1, stage III = 8, plasma-cell leukemia = 1) who received an allogeneic transplant with PBSC. Their age ranged between 35 and 53 years (median 45). All were HLA-identical to their sibling donors. Prior to allograft, six patients received standard-dose chemotherapy (DAV or CY-Dexa) and four a sequential intensified scheme with autologous PBSC support. At the time of transplantation, three patients were in CR, three in PR, three had refractory disease, one progressive disease. Patients were conditioned with busulfan-melphalan (n = 9) or busulfan-cyclophosphamide (n = 1), and were allografted with unmanipulated PBSC obtained by apheresis after treatment with G-CSF alone (n = 6) or GM-CSF followed by G-CSF (n = 4). All patients engrafted, with 0.5 × 10 9 /l PMN and 50 × 10 9 /l platelets on (median) day 13. Four patients had уgrade II acute GVHD (grade II in 3, grade III in 1). Following allograft, CR was achieved in 71% patients. Eight are currently alive, with six in CR at a median of 18.5 months (range 7-28) from the transplant. Two patients died, 1 and 4 months from the allograft, respectively, and one is alive with progression. A PCR analysis of IgH rearrangement showed that residual disease was no more molecularly detectable in four out of seven evaluated patients following allograft. The results suggest that PBSC may improve the therapeutic efficacy of allogeneic transplant in MM, not only by a reduction of TRM but also by an improvement of rate and quality of response.
For more than two decades the treatment of multiple myeloma (MM) has made little substantial progress, and attempts to overcome the results of standard melphalanprednisone with other conventional-dose drug combinations has met with little success. 1 Better results in terms of remission and survival have been offered by more intensive treatment with autologous stem cell support, 2 but there is no evidence that this will eventually result in effective cure of the disease.
Allogeneic bone marrow transplantation (alloBMT) has two theoretical advantages over the autograft. One is the lack of neoplastic harvest contamination; 3 the other is a direct anti-tumor activity through a putative graft-versusmyeloma effect. [4] [5] [6] [7] Both retrospective, multi-center [8] [9] [10] and single-center studies 11 show more sustained complete remissions after alloBMT. However, a relatively high transplant-related mortality (TRM) limits its wide application. A case-matched study 12 showed that, as a consequence of the higher TRM, results of alloBMT may be worse in comparison with autologous, despite an increased progression rate observed with the latter.
Efforts to improve results of alloBMT in MM should address TRM reduction. In autologous transplantation, the use of peripheral blood stem cells (PBSC) has contributed to shortening cytopenia and reducing complications in a variety of hematologic disorders, including MM. [13] [14] [15] [16] More recently, PBSCs have also been used for allogeneic transplantation, with similar advantages in terms of hematopoietic reconstitution, and without an increase in incidence and severity of acute GVHD. [17] [18] [19] [20] [21] With these premises, 10 patients with MM received a PBSC allograft at our institutions. We report the initial clinical and biological results showing that this modality is feasible in this category of patients and may offer an advantage in terms of toxicity and overall outcome. We also show that after allogeneic PBSC transplantation, MM patients may achieve not only clinical but also molecular remission.
Patients and methods

Patient and donor characteristics
The records of all patients who received an allogeneic PBSC transplant for MM between 1995 and 1997 were reviewed. MM patients had been admitted to the program of allogeneic PBSC transplantation provided they (1) were stage II or III MM; (2) had an HLA-matched, MLC nonreactive sibling donor; and (3) recipient age was Ͻ60 years and donor age Ͼ18 years. Criteria for exclusion were (1) abnormal cardiac function (systolic ejection fraction Ͻ50%); (2) chronic respiratory disease; (3) abnormal liver function; (4) psychiatric disease; and (5) HBsAg or HIV positivity of either patient or donor. The investigational protocol was approved by the regional Bio-ethical Committee and both recipients and donors were required to sign a written informed consent before admission.
There were 10 patients, nine males and one female. Their age ranged from 35 to 53 years (median 45). All were advanced stage 22 with one patient being classified stage II (No. 6), one plasma cell leukemia (No. 2) and the remainder stage III. Their characteristics are shown in Table 1 .
Debulking treatments prior to allograft
Tumor burden reduction prior to transplantation was effected with different chemotherapy (CT) programs. A single CT regimen was employed in six patients. It consisted of three to six courses of DAV 23 for four patients. Each DAV regimen included adriamicin at 50 mg/m 2 , vincristine 1.5 mg/m 2 at day 1 and dexamethasone 40 mg for 4 consecutive days. Two more patients received six and 12 courses, respectively, of cyclophosphamide (CY) given at 1.2 g/m 2 /day for 2 days along with 40 mg dexamethasone for 4 consecutive days. A multicyclic dose-intensive chemotherapy (MIC) with i.v. melphalan at intermediate doses and autologous stem cell support was employed in the remaining four patients, according to a recently published protocol. 24 The schedule included an initial phase with two DAV courses; cyclophosphamide was then given at 5 g/m 2 followed by G-CSF at 10 g/kg/day; PBSC were Non sec = non secreting MM; PCL = plasma-cell leukemia; CT = chemotherapy; Cy = cyclophosphamide; MPH = melphalan; PDN = prednisone; Bu = busulfan; Cy/Dexa = cyclophosphamide 2 × 1. The courses of high-dose melphalan were followed by the infusion of autologous PBSC collected after the previous Cy treatment. collected and harvested during hematologic recovery; melphalan was then administered at 80-100 mg/m 2 and a fraction of harvested PBSC was reinfused; administration of intermediate-dose melphalan with autologous stem cell rescue was repeated twice in three patients and three times in one patient. Overall, debulking treatments were well tolerated without any serious complications.
Donor PBSC mobilization and collection
To mobilize stem cells, six donors received subcutaneous G-CSF (Amgen, Thousand Oaks, CA, USA) in two divided daily injections of 10 g/kg/day for 5 days before starting the aphereses and until the end of the collections. 25 In four other donors, mobilization consisted of subcutaneous GM-CSF (Leucomax; Sandoz Pharma, Basel, Switzerland) 5 g/kg/day for 2 days, followed by G-CSF 16 g/kg/day until the end of collections. Donors were treated as outpatients in all cases. A continuous (CS-3000 'Plus', Baxter, Deerfield, IL, USA, or the AS-104, Fresenius AG, Bad Homburg, Germany) or a discontinuous-flow device (MCS 3p, Haemonetics, Braintree, MA, USA) was employed for mononuclear cell collection. Aphereses were regularly run on subsequent days through antecubital veins. Approximately 8 to 13 blood volumes were processed, at a flow rate of 50 ml/min. Cells were stored at 4°C until infusion.
Cell characterization
For surface marker analysis, peripheral blood and leukapheresis product samples were immunofluorescence-labelled using the monoclonal antibodies: CD3 (Leu-4), CD4 (Leu3a), CD8 (Leu-2a), CD19 (Leu-12), CD20 (Leu-16), CD56 (Leu-19), CD34 (HPCA-2, FITC), and Ig isotype controls (Becton Dickinson, San José, CA, USA). Samples were acquired on a FACScan and analyzed using the Lysis II software (Becton Dickinson), 26 and CFU-GM in apheresis samples were estimated by in vitro short-term clonogenic assays as reported elsewhere. 20 Cellular content of the graft for each patient is shown in Table 2 .
Transplant, conditioning and supportive care
Recipients were conditioned with busulfan and melphalan (busulfan 14-16 mg/kg; melphalan 140 mg/m 2 , nine patients), or with busulfan and cyclophosphamide (busulfan 16 mg/kg; cyclophosphamide 200 mg/kg, one patient). Cells were infused through an atrial catheter on a single day (day 0) in six patients, and over 3 subsequent days (days 0, 1, 2) in four patients. No patient received G-CSF following transplantation. Patients were nursed in sterile single rooms, and received antimicrobal prophylaxis and irradiated blood products. All were monitored weekly for CMV infection, by the shell-vial, the antigenemia assay and the PCR assay 20, 27 on blood leukocytes. In addition, BAL was performed on day +40 if the previous tests were negative. CMV infection was pre-emptively treated with ganciclovir 5 mg/kg i.v. twice daily for 7 days, followed by 5 mg/kg five times per week until day +100.
GVHD prophylaxis and treatment
Acute and chronic GVHD were graded according to published criteria. 28 GVHD prophylaxis consisted of i.v. cyclosporin A (CsA) and methotrexate (MTX) in all cases. In six patients, CsA was given intravenously at the dose of 2.5 mg/kg from day −1, and MTX at the dose of 15 mg/m 2 i.v. on day +1, followed by 10 mg/m 2 on days +3, +6, and +11 with leucovorin rescue. The day +11 dose was omitted in cases of severe mucositis or fever. Four patients received lower doses of CsA/MTX (CsA 1 mg/kg i.v. and MTX 10, 8, 8 mg/m 2 i.v. on day +1, +3, +6, respectively). In the absence of chronic GVHD, CsA was gradually tapered after day +180, and stopped 4 to 6 weeks later. Treatment of acute GVHD was 6-methylprednisolone 2 mg/kg i.v. for 10 days, followed at halving the dose by intervals of 5 days. Non-responding patients received an increased dose to 5-10 mg/kg/day.
Definition of response
Complete remission (CR) was defined as the absence of monoclonal protein on serum electrophoresis and immunofixation analysis, and in cases of BJ proteinuria by its disappearance, along with 5% or fewer plasma cells with normal morphology, and disappearance of other plasma cell tumors. A partial response (PR) was a decrease of Ͼ50% in the serum paraprotein level or BJ protein in urine.
Patients with a less than partial response were considered as resistant (resistant disease, RD). Progression was defined as a Ͼ25% increase of paraprotein, and relapse as paraprotein reappearance and/or marrow infiltration and/or of extraskeletal myeloma in patients otherwise in CR.
Molecular studies for chimerism and for detection of residual myeloma cells
To assess chimerism, the pattern of highly informative microsatellite or minisatellite was investigated by PCR analysis of donor peripheral blood and bone marrow preparations, using oligoprimers flanking the repeats units. 20 The following human hypervariable regions were used: D1S80, 33.6, YNZ22, D5S422, D5S421. Following PCR, microsatellite products were electrophoresed through a 6% polyacrylamide gel, while minisatellite products were subjected to electrophoresis in a 1% agarose gel. Gels were stained with ethidium-bromide and DNA visualized under UV. Clonal rearrangements of the immunoglobulin heavy chain gene locus (IgH) were used as PCR markers to detect minimal residual disease (MRD). To amplify rearranged IgH variable regions (VDJ), RNA or genomic DNA were isolated as previously described. 3 VDJs were amplified starting from genomic DNA or total cDNA, depending on sample availability. Amplifications were performed as previously described. 3 Direct sequencing of amplified VDJs was performed using the Promega fmol sequencing system as previously described. 29 The analysis of sequencing was performed using the PC-GENE software (IntelliGenetics, Mountain View, CA, USA). One microgram of RNA was transcribed into total cDNA and amplified using CDR2 and JH primers (in three cases 1 g of DNA was used, because RNA was not available), 20% of the PCR product was analyzed by agarose gel electrophoresis, blotted overnight, and hybridized to CDR3 probes end-labeled with ␥-32 P-ATP as described previously.
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Results
Hematopoietic engraftment, GVHD and overall toxicity
All patients engrafted promptly and steadily, with a median of 13 days to achieve both an absolute neutrophil count (ANC) Ͼ0.5 × 10 9 /l and a platelet count Ͼ50 × 10 9 /l. Transfusion needs were minimal, with a median of one packed red cell (PRC) unit and two single-donor platelet units per patient. All but one patient developed fever, but no severe infectious complications occurred during hematologic recovery and hospital stay was relatively short. Seven patients developed CMV infection but all responded to preemptive ganciclovir treatment. None developed overt CMV disease. Overall, acute GVHD developed in eight patients (see Table 3 ). This was grade I in four, grade II in three, and grade III in one patient. Seven patients were treated with steroids: six responded, two of them only partially while the other four experienced a complete response to steroids; one more patient, in spite of relatively mild acute GVHD, developed extensive chronic GVHD which contributed to an early fatal outcome (see below). Overall, chronic GVHD developed in six out of nine evaluable patients. It was limited in four and extensive in two. Two patients died after transplantation. The one with extensive chronic GVHD died of an interstitial pneumonia syndrome at 4 months. A second patient died at 1 month from thrombotic thrombocytopenic purpura (TTP) that proved resistant to plasma exchange. This patient had no prior complications which might have precipitated TTP development. Indeed he had prompt hematologic engraftment, no infectious complications and steroid-responsive, grade I acute GVHD.
Disease response and overall results
At the time of transplantation, three patients were in CR, three in PR, three had RD and one PD. At post-transplant evaluation, eight were in CR and two in PR (Table 1) . Transplantation induced CR in five out of the seven (71%) patients showing disease persistence before conditioning. Beside the two patients who died of treatment-related complications, the remaining six patients acquiring or maintaining CR after transplantation are alive with no sign of disease recurrence. One more patient in PR after transplantation is alive with stable minimal disease. Disease progression occurred in a single patient who was in PR after transplantation: he had a residual paravertebral myeloma mass, in the absence of bone marrow plasma cell infiltration or serum monoclonal protein. Progression consisted of a rapid increase in the size of the mass 7 months following transplantation, with no response to radiation therapy. The patient is currently receiving donor lymphocyte infusions. Thus, eight patients are currently alive, and six are free of disease 7 to 28 months (median 18.5) from the allograft. Six patients have chronic GVHD.
Chimerism and residual disease
The study of micro-and mini-satellite patterns shows that all nine patients were evaluated or became full-donor chimeras in their bone marrow cells as early as 1-3 months after transplantation. In one (patient No. 7) recipient cells reappeared 6 months post-transplant (mixed chimera), while he remained in clinical remission (data not shown). Concerning evaluation of MRD, a clonal product was obtained and the IgH rearrangement of the neoplastic clone successfully sequenced in seven patients (see Table 1 ). Disappearance of disease at a molecular level was documented in four out of the seven (Nos 1, 3, 4, 8 
Discussion
Here, we show the initial results of allogeneic PBSC transplantation in MM. Although the study contains only retrospective data of a small patient cohort, it strongly suggests that in MM, as in other conditions, the use of PBSC instead of marrow is not accompanied by undue toxicity, GVHD or graft failure. More interestingly, it shows a high remission rate, a low TRM and the elimination of molecularly detectable disease in some patients despite the poor prognostic features.
Transplantation was followed by rapid hematologic recovery. The post-transplant course was uneventful in most cases, with low transfusion requirements and short duration of fever. None of the patients developed CMV disease despite the occurrence of CMV infection (seven out of 10 patients). Interstitial pneumonia developed leading to death in a single case, but CMV was not found in blood and BAL.
The rapid engraftment probably contributed to the low TRM. 12 In comparison with marrow, PBSC grafts show a higher content of progenitor cells, [17] [18] [19] [20] 30 which is considered a major determinant of transplant outcome. In a retrospective analysis, patients receiving marrow grafts with a low CFU-GM count had lower platelet counts at day +50, higher TRM and lower overall survival. 31 In another study, CD34
+ cell dose was found to be the only variable predicting TRM. 32 The large number of progenitors may be responsible for the relatively low TRM observed in our patients.
Pre-transplant treatment may also influence allograft tolerance. In fact, no deaths occurred among patients previously treated with conventional-dose regimens, ie DAV or Cy-Dexa. By contrast, two out of four patients receiving the intensified debulking died shortly after transplantation, one of them with multi-organ toxicity. In an EBMT study, 10 favorable results were associated with a single line of therapy before transplantation. In another study from Seattle, 11 the time from diagnosis to transplant was the only variable influencing TRM. The prognostic influence of time to transplant is also stressed in a recent report of 13 patients 33 transplanted early, nine of whom were surviving diseasefree 7 to 70 months post-transplant. Unfortunately, in all these studies neither the source nor the number of stem cells was analyzed for influence on TRM. In our series, patients received a single line of therapy and were transplanted at a median of 8 months from diagnosis. The two patients with a fatal outcome had no adverse features, had disease responsive to initial treatment and were transplanted early after diagnosis. These results confirm that an early allograft may be associated with a favorable outcome. They also suggest that intensive therapy prior to allograft may carry an increased risk of TRM.
Non-T cell-depleted PBSC were infused for allografting. This implied a high lymphocyte content (median 2.4 × 10 8 /kg CD3 + cells) of grafts, with a CD3 + cell dose at least 1-log superior to that of a marrow transplant. However, no increase in acute GVHD was observed, as already reported in retrospective analyses 21, 30 of bone marrow vs PBSC transplants. In animals, G-CSF treatment has been shown to suppress the ability of CD4 + and CD8 + T cells to induce acute GVHD. 34 The role of lymphocytes in allogeneic transplantation is not confined to rejection and GVHD. Alloreactive lymphocytes may contribute to disease eradication, as shown by the increased relapse after T cell depletion, 35 and by its successful treatment with donor lymphocytes. 36, 37 This mechanism may also operate in MM. Two patients with recurrent MM after allogeneic BMT (partly T cell-depleted) received leukocyte infusions from their original donors. Both developed GVHD and achieved complete remissions. 5 A patient with MM, who relapsed with multiple solid subcutaneous plasma cell tumors after allogeneic sibling BMT received donor CD3 + cells. Five days later the tumors started to shrink and then completely vanished. 7 In a recent report, donor immunization with recipient myeloma immunoglobulin before transplantation led to production of a myeloma idiotype-specific T cell response in the recipient. 38 In the present study, all patients had advanced stage myeloma and some had additional adverse features, such as BJ type, plasma-cell leukemia or non-secretory form. At the time of transplantation, four patients had refractory or progressive disease. Nonetheless, after transplant we recorded 100% overall response and 71% complete remissions. Eight patients are currently alive, and six are in CR at a follow-up time of 7-28 months. An explanation for the excellent results in terms of CR achievement and maintenance, may be the large numbers of T-lymphocytes in the graft inoculum.
Residual disease was evaluated by a PCR-based analysis using patient-specific sequences from the rearranged variable region (VDJ) of IgH chain genes. The assay is highly sensitive, allowing the detection of one tumor plasma cell in 10 5 -10 6 normal cells. Informative data were obtained in seven patients: four attained molecular remission after transplantation. Two of them died early while in remission; one more patient had an isolated paravertebral plasmacytoma 7 months later, while still in molecular remission, along with a normal marrow, 100% donor-cell type. A fourth patient maintains a molecular remission more than 2 years from transplant. The number of patients and their short follow-up does not allow us to draw firm conclusions, but the frequent occurrence of PCR-negativity suggests a role for peripheral stem cells in disease eradication.
The results of our study show that in MM allogeneic PBSC transplantation is an effective treatment and may be indicated for younger patients with an HLA-compatible donor. The procedure is associated with a low toxicity and offers high probabilities of complete remission even at molecular level.
